NIH Martin Delaney Collaboratory
Science that
brings us
closer to a cure.
We bring laboratory discovery, clinical research, and community insight together to pursue lasting HIV control without daily medication.
REACH · Research Enterprise to Advance a Cure for HIV
Built on collaboration ↗Clinical progress · ACTG A5386
A5386 broke new ground.
Now we build on it.
HIV’s reservoir has been one of the toughest barriers to a cure. A5386 delivered a measurable reduction in genetically intact HIV, alongside exciting clues to control without daily treatment.
reduction in the intact HIV reservoir after five doses of N-803, an immune-stimulating treatment
participants remained off standard HIV medication for at least 24 weeks in updated REACH follow-up
Remodeling toward stem-like T cells
Itzy Miller’s analysis found a shift toward more stem-like, less exhausted CD8 T cells—a profile associated with HIV control after the study interventions. These cells have features that support immune renewal and sustained responses.
Reservoir reduction was measured during treatment. The six-participant milestone comes from updated REACH follow-up as of September 10, 2026. Time off antiretroviral therapy (ART) and study-defined viral control are different outcomes.
Explore the findings and what comes next
Enlarge figure Scheck et al. · AIDS 2026, OAA1502, Figure 1 · JIAS. Reproduced unchanged under CC BY 4.0.
The people behind the findings
Science across REACH
Different expertise.
Shared progress.
HIV latency, antibody design, and immune-cell biology: complementary approaches to the questions a cure must answer.
Why HIV falls silent
Paul Bieniasz, Frauke Mücksch, and colleagues investigate how HIV’s position within a cell’s DNA helps shape whether the virus stays active or falls silent.
Explore the study
Better antibody tools
Wei Li and colleagues combine computational design with laboratory testing to improve antibody-based research tools, including tools that recognize HIV.
Explore the study
Why infected cells survive
Foundational work by Kiera Clayton and colleagues showed how HIV-infected macrophages, a type of immune cell, can resist elimination by natural killer cells.
Explore the studyExplore our research
Four questions driving us forward.
HIV can survive treatment in a small pool of infected cells called the reservoir. These connected areas help us understand and overcome it.
Understand the reservoir
What allows HIV to persist in rare cells despite effective treatment?
Explore this research 02Help the immune system control HIV
How can immune cells and antibodies help contain HIV without daily medication?
Explore this research 03Help the immune system find infected cells
Why do some infected cells survive an immune attack?
Explore this research 04Understand how HIV stays silent
How does HIV’s place in a cell’s DNA shape its activity?
Explore this researchReservoir science · Nature, 2026
A rare window into
HIV’s last strongholds.
Authentic reservoir clones (ARCs) bring some of the hardest-to-study infected cells within reach. Derived from cells donated by people living with HIV, they help reveal why the reservoir survives and where it is vulnerable.
Work from the Jones and Nussenzweig laboratories is opening new questions about immune clearance.
Explore the reservoir discovery ↗nature
Research article · February 24, 2026
Dynamic antigen expression and cytotoxic T cell resistance in HIV reservoir clones
Ferreira, Herrera and colleagues
Jones & Nussenzweig laboratories
Science shaped by community
Progress starts
with listening.
People living with HIV help shape the questions we ask. With AVAC and our community advisory board, REACH connects cure science with community insight.
A growing body of discovery
Publication records associated with REACH
Explore the science.
Follow the evidence.
Search the NIH RePORTER bibliography by topic, researcher, or year. Each record links to its source, with preprints and related versions clearly identified.
Browse all 93 publications ↗A collaborative enterprise
One purpose.
A collective effort.
REACH connects laboratory scientists, clinicians, and community partners as part of the NIH Martin Delaney Collaboratories.
Our next phase, which began in August 2026, builds on the discoveries and clinical results that brought us here.
The REACH network
Many institutions.
One shared ambition.
Explore our domestic partner institutions and the people behind the work.
Weill Cornell Medicine
The Rockefeller University
University of Pittsburgh
UMass Chan Medical School
Fred Hutch Cancer Center
Yale University
University of Louisville
Washington University in St. Louis
University of Pennsylvania
George Washington University
Johns Hopkins University
Massachusetts General Hospital / Ragon Institute
AVAC
ImmunityBio